Orlando, FLORIDA5 Active Studies

Ovarian Cancer Clinical Trials in Orlando, FLORIDA

Find 5 actively recruiting ovarian cancer clinical trials in Orlando, FLORIDA. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
1,211
Enrolling

Recruiting Ovarian Cancer Studies in Orlando

RecruitingOrlando, FLORIDANCT06619236

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to che...

530 participants
Genmab
View Study Details
RecruitingOrlando, FLORIDANCT06072781

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progr...

270 participants
Verastem, Inc.
View Study Details
RecruitingOrlando, FLORIDANCT05281471

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active...

186 participants
Genelux Corporation
View Study Details
RecruitingOrlando, FLORIDANCT05128825

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Canc...

170 participants
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
View Study Details
RecruitingOrlando, FLORIDANCT05512208

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid...

55 participants
University of Oklahoma
View Study Details

About Ovarian Cancer Clinical Trials in Orlando

Ovarian cancer originates in the ovaries or fallopian tubes and is often called a "silent killer" due to subtle early symptoms. It is the fifth leading cause of cancer death among women. Treatment typically involves surgery and chemotherapy, with newer targeted therapies showing promise.

There are currently 5 ovarian cancer clinical trials recruiting participants in Orlando, FLORIDA. These studies are seeking a combined 1,211 participants. Research is being sponsored by Genmab, Verastem, Inc., Genelux Corporation and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ovarian Cancer Clinical Trials in Orlando — FAQ

Are there ovarian cancer clinical trials in Orlando?

Yes, there are 5 ovarian cancer clinical trials currently recruiting in Orlando, FLORIDA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Orlando?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Orlando research site will contact you about next steps.

Are clinical trials in Orlando free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Orlando studies also compensate for your time and travel.

What ovarian cancer treatments are being tested?

The 5 active trials in Orlando are testing new therapies including novel drugs, biologics, and treatment approaches for ovarian cancer.

Data updated March 2, 2026 from ClinicalTrials.gov